Terms: = Lung cancer AND BAP1, DKFZp686N04275, 8314, ENSG00000163930, Q92560, KIAA0272, hucep-6, HUCEP-13, FLJ37180, FLJ35406 AND Treatment
85 results:
1. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.
van Kooten JP; Dietz MV; Dubbink HJ; Verhoef C; Aerts JGJV; Madsen EVE; von der Thüsen JH
Clin Exp Med; 2024 Apr; 24(1):80. PubMed ID: 38642130
[TBL] [Abstract] [Full Text] [Related]
2. bap1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
Yuce TH; Ak G; Metintas S; Dundar E; Roe OD; Panou V; Metintas M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):38. PubMed ID: 38280040
[TBL] [Abstract] [Full Text] [Related]
3. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a bap1 mutation.
Lee J; Turetsky J; Nasri E; Rogers SC
BMJ Case Rep; 2023 Dec; 16(12):. PubMed ID: 38142057
[TBL] [Abstract] [Full Text] [Related]
4. Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell lung cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.
Passiglia F; Righi L; Bironzo P; Listì A; Farinea G; Capelletto E; Novello S; Merlini A; Scagliotti GV
Clin Cancer Res; 2024 Mar; 30(5):959-964. PubMed ID: 38109438
[TBL] [Abstract] [Full Text] [Related]
5. Combined Inhibition of EZH2 and FGFR is Synergistic in bap1-deficient Malignant Mesothelioma.
Badhai J; Landman N; Pandey GK; Song JY; Hulsman D; Krijgsman O; Chandrasekaran G; Berns A; van Lohuizen M
Cancer Res Commun; 2024 Jan; 4(1):18-27. PubMed ID: 38054839
[TBL] [Abstract] [Full Text] [Related]
6. Updates in Management of Malignant Pleural Mesothelioma.
John A; O'Sullivan H; Popat S
Curr Treat Options Oncol; 2023 Dec; 24(12):1758-1789. PubMed ID: 37975977
[TBL] [Abstract] [Full Text] [Related]
7. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.
Dietz MV; van Kooten JP; Paats MS; Aerts JGVJ; Verhoef C; Madsen EVE; Dubbink HJ; von der Thüsen JH
ESMO Open; 2023 Aug; 8(4):101600. PubMed ID: 37453150
[TBL] [Abstract] [Full Text] [Related]
8. Peritoneal papillary mesothelioma in situ: bap1 mutation with indolent behavior for 15 years.
Vitlarov N; Burtscher E; Pfeiffenberger E; Wahl A; Hodja V; Jasarevic Z; Kashofer K; Offner FA
Virchows Arch; 2023 Dec; 483(6):873-878. PubMed ID: 37428268
[TBL] [Abstract] [Full Text] [Related]
9. SETDB1 tumour suppressor roles in near-haploid mesothelioma involve TP53.
Xu M; Tu Y; Bi W; Lundberg MZ; Klooster I; Fletcher JA; Ou WB
Br J Cancer; 2023 Aug; 129(3):531-540. PubMed ID: 37369845
[TBL] [Abstract] [Full Text] [Related]
10. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
Borea F; Franczak MA; Garcia M; Perrino M; Cordua N; Smolenski RT; Peters GJ; Dziadziuszko R; Santoro A; Zucali PA; Giovannetti E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298116
[TBL] [Abstract] [Full Text] [Related]
11. New Markers for Management of Mesothelioma.
Nash A; Firth Née Phan T; Creaney J
Semin Respir Crit Care Med; 2023 Aug; 44(4):491-501. PubMed ID: 37253383
[TBL] [Abstract] [Full Text] [Related]
12. Diffuse intrapulmonary mesothelioma mimicking pulmonary lepidic adenocarcinoma: a rare case report and review of the literature.
RanYue W; ChunYan W; Likun H; LiPing Z; JieLu L; ZhengWei D
Diagn Pathol; 2023 May; 18(1):64. PubMed ID: 37194050
[TBL] [Abstract] [Full Text] [Related]
13.
Bulutay P; Vatansever D; Taskiran C; Mericoz CA; Tokat F; Kapucuoglu N; Kulac I
Indian J Pathol Microbiol; 2023; 66(2):392-395. PubMed ID: 37077094
[TBL] [Abstract] [Full Text] [Related]
14. Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma.
Marmarelis ME; Wang X; Roshkovan L; Grady CB; Miura JT; Ginsberg MS; Ciunci CA; Egger J; Walker S; Cercek A; Foote MB; Litzky LA; Nash G; Haas AR; Karakousis GC; Cengel KA; Katz SI; Zauderer MG; Langer CJ; Offin M
JAMA Netw Open; 2023 Mar; 6(3):e232526. PubMed ID: 36897589
[TBL] [Abstract] [Full Text] [Related]
15. Mesothelioma In Situ Mimicking Well-differentiated Papillary Mesothelial Tumor.
Galateau-Salle F; Hamilton T; MacNeill A; Hofman V; Sequeiros R; Sagan C; Le Stang N; Churg A
Am J Surg Pathol; 2023 May; 47(5):611-617. PubMed ID: 36876759
[TBL] [Abstract] [Full Text] [Related]
16. Mesotheliomas and Benign Mesothelial Tumors: Update on Pathologic and Imaging Findings.
Bonde A; Singh R; Prasad SR; Kamireddy D; Aggarwal A; Ramani N; Saboo S; Shanbhogue K; Dasyam AK; Katabathina VS
Radiographics; 2023 Mar; 43(3):e220128. PubMed ID: 36757881
[TBL] [Abstract] [Full Text] [Related]
17. Well-differentiated Papillary Mesothelial Tumour of the Tunica Vaginalis Testis - A Rare Lesion, but one Pathologists Should Know About Two Patient Reports and a Review of the Literature.
Kläger J; Oberndorfer F; Brunel C; Veser J; Compérat E
Int J Surg Pathol; 2023 Sep; 31(6):1126-1131. PubMed ID: 36624609
[TBL] [Abstract] [Full Text] [Related]
18. Genomic landscape of pleural and peritoneal mesothelioma tumours.
Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A
Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075
[TBL] [Abstract] [Full Text] [Related]
19. A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.
Nguyen TT; Lee HS; Burt BM; Amos CI; Cheng C
Br J Cancer; 2022 Nov; 127(9):1691-1700. PubMed ID: 35999269
[TBL] [Abstract] [Full Text] [Related]
20. Localized Malignant Peritoneal Mesothelioma (LMPeM) in Women: A Clinicopathologic Study of 18 Cases.
Malpica A; Euscher ED; Marques-Piubelli ML; Miranda RN; Raghav KP; Fournier KF; Ramalingam P
Am J Surg Pathol; 2022 Oct; 46(10):1352-1363. PubMed ID: 35713639
[TBL] [Abstract] [Full Text] [Related]
[Next]
